From Archives to Decisions: Multi-Agent Pharmaceutical Co-Scientist for Traceable Drug Discovery and Reverse Translation

Xiaochen Zheng, Alvaro Serra, Ilya Schneider Chernov, Maddalena Marchesi, Eunice Musvasva, Tatyana Y. Doktorova · 2025

Read From Archives to Decisions: Multi-Agent Pharmaceutical Co-Scientist for Traceable Drug Discovery and Reverse Translation by Xiaochen Zheng, Alvaro Serra, Ilya Schneider Chernov, Maddalena Marchesi, Eunice Musvasva, Tatyana Y. Doktorova (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2511-18259.txt.

Introduction

Xiaochen Zheng, Alvaro Serra, Ilya Schneider Chernov, Maddalena Marchesi, Eunice Musvasva, and Tatyana Y Doktorova introduce DiscoVerse, a multi-agent AI assistant for drug research at Roche. Pharma archives hold decades of work, much of it from programmes that were stopped. And reusing that knowledge could guide new projects in reverse translation, working back from human data to the lab. In practice the archives are vast and scattered, so reuse rarely happens.

DiscoVerse answers staff questions with evidence-linked replies: it retrieves data, joins documents, summarises findings, and keeps institutional memory intact. Experts judged its source-linked outputs on a slice of one hundred and eighty molecules drawn from more than four decades of Roche research. The team presents it as a human-in-the-loop co-scientist whose every claim can be traced to its source.

Catalog record

CREATORXiaochen Zheng, Alvaro Serra, Ilya Schneider Chernov, Maddalena Marchesi, Eunice Musvasva, Tatyana Y. Doktorova
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2511-18259

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

From Archives to Decisions: Multi-Agent Pharmaceutical Co-Scientist for Traceable Drug Discovery and Reverse Translation Xiaochen Zheng, Alvaro Serra, Ilya Schneider Chernov, Maddalena Marchesi, Eunice Musvasva, Tatyana Y. Doktorova Abstract Pharmaceutical research and development has accumulated vast, heterogeneous archives of data. Much of this knowledge stems from discontinued programs, and reusing these archives is invaluable for reverse translation. However, in practice, such reuse is often infeasible. In this work, we introduce DiscoVerse , a multi-agent co-scientist designed to support pharmaceutical research and development. The system implements semantic retrieval, cross-document linking, and auditable synthesis on a large historical corpus from Roche. To validate our approach at real-world scale, we selected a subset of 180 molecules from the Roche research repositories, covering over 0.87 billion BPE 40 tokens and more than four decades of research. Designed as a human-in-the-loop assistant, DiscoVerse enables domain-specific queries by delivering evidence-based answers: it retrieves relevant data, links across documents, summarises key findings and preserves institutional memory. Given that automated evaluation metrics are poorly aligned with scientific utility, we evaluate the performance of DiscoVerse using blinded expert evaluation of source-linked outputs. To our knowledge, this is the first agentic framework systematically assessed on real pharmaceutical data for reverse translation, enabled by authorized access to confidential, end-to-end drug-development archives. Our contributions include role-specialized agent designs aligned with scientist workflows; human-in-the-loop support for reverse translation; expert evaluation; and a large-scale demonstration showing promising answer accuracy and decision-making insights. In brief, across seven benchmark queries covering 180 molecules, DiscoVerse achieved near-perfect recall ( ≥ 0.99 \geq 0.99 ) with moderate precision ( 0.71 − 0.91 0.71-0.91 ), while qualitative assessments of discontinuation rationale and organ-specific toxicity showed faithful, source-linked synthesis across preclinical and clinical evidence (see Tab. 2 ). 1 Introduction The pharmaceutical industry has generated vast repositories of experimental data over decades. For each drug candidate, companies typically produce extensive internal study reports, raw experimental data, toxicological findings, histopathological evaluations, nonclinical and clinical study presentations, and documentation of decision-making processes and content throughout drug discovery and development. Collectively, these materials represent an invaluable yet underutilized resource. Embedded within them are insights into treatment-related findings, target organ toxicities, information on the safety and efficacy profiles of the drug candidates as well as detailed experimental methodologies. A significant portion of this archived information originates from discontinued drug candidates halted at various stages of development. Such attrition is inherent to pharmaceutical research and development, yet these data are far from failures: through reverse translation 25 ; 20 ; 46 ; 42 , insights from clinical outcomes can refine earlier - stage research, turning therapeutic failures into opportunities to identify new targets and biomarkers 41 and to apply lessons from clinical pharmacology and regulatory reviews to new therapies 9 . A good example of such reverse translation efforts is discovery of a new therapeutic target (the TGF - \beta pathway 31 ) while exploring clinical observations of treatment resistance and tracing them back to the underlying biology that can be therapeutically modulated. A challenge, however, in this reverse translation exercise is that end - to - end drug development produces thousands of heterogeneous documents dispersed across large organizations and external partners, with inconsistent naming conventions and project - specific terminology that evolves over time. This fragmentation makes systematic retrieval via browsing or simple keyword search infeasible—synonymy and nomenclature drift, facts locked in tables, and context - dependent phrasing yield high false negatives (missing evidence) and high false positives (noise). Overcoming these barriers requires semantic retrieval , cross - document linking , preclinical–clinical data alignment and auditable synthesis 20 ; 18 . When curated, structured, and made searchable, these legacy datasets become reusable assets for quantitative analysis, machine learning, and predictive toxicology, enabling cross - program pattern recognition across molecular structures, pharmacological targets, toxicological profiles, and safety margins, and ultimately improving decision - making while reducing redundant experimentation. Recent large language models (LLMs)(e.g., ChatGPT 1 , Gemini 43 , Claude 3 , Qwen 4 , DeepSeek 29 ; 16 ) can read and synthesize massive unstructured corpora and, when domain - adapted, generate concise, source - grounded summaries of complex biomedical and medical text 44 ; 45 ; 50 ; 13 ; 51 ; 11 ; 27 . This makes LLMs a practical way to drive insights across programs, applying consistent criteria over many reports so evidence that humans might miss still surfaces. However, pharmaceutical research and development presents unique challenges that expose the limitations of single-agent LLM approaches. It is a highly specialized domain in which each study is context-specific—differing in endpoints, assays, and terminologies—making it difficult to provide standardized instructions or representative examples for large language models to learn from. Moreover, large pharmaceutical companies often collaborate with multiple external contract research organizations (CROs) to optimize distribution of internal capabilities, costs, and speed. While these distributed processes enhance productivity, CROs also introduce additional heterogeneity. Consequently, single-agent LLMs often struggle to generalize robustly from sparse or non - representative sources of information 35 ; 39 ; 34 . These challenges are further compounded by siloed data sources and the gradual drift of domain-specific terminology over time, which collectively hinder model consistency and reliability. We therefore adopt a multi - agent system (MAS) 6 ; 19 ; 52 ; 23 ; 49 ; 14 ; 55 architecture with role - specialized agents for retrieval, research, verification, and synthesis. By enabling agents to interact and critique one another and enforcing source - grounded outputs, MAS better handles sparse demonstrations while maintaining traceable, auditable reasoning chains, which is an essential requirement in regulated pharmaceutical research. Emerging empirical evidence further substantiates the advantages of MAS over single-agent LLMs, particularly in specialized domains with limited instructional examples 48 . For instance, Chen et al. 7 report that MAS exhibits enhanced diagnostic capabilities relative to individual LLMs in clinical domains. Recent controlled evaluations 49 ; 22 ; 55 ; 52 ; 21 ; 54 further demonstrate that appropriately designed MAS can achieve human-level performance in complex medical tasks, underscoring the viability of this approach for pharmaceutical research and development 38 . Building on MAS framework, we developed DiscoVerse , a multi-agent co-scientist tailored specifically for pharmaceutical knowledge ingestion and translational support across the drug development lifecycle. The system integrates and aligns preclinical and clinical data, enabling systematic preclinical–clinical mapping and comparison. Through its role-specialized agents for retrieval, research, validation, and synthesis, DiscoVerse can efficiently uncover relevant information from historical archives to link preclinical observations with clinical outcomes. In design, DiscoVerse functions as a human-in-the-loop assistant: project teams can query it with questions such as “What was the main reason for discontinuation of drug X?”. By retrieving and connecting molecular, toxicological, and clinical evidence, DiscoVerse supports reverse translation, allowing scientists to derive meaningful insights from past clinical experiences and apply them to current research programs. The key contributions of our framework are four-fold: (i) specialised agent designs that mirror scientist workflows, each optimised for a distinct sub-task with external knowledge available; (ii) integration with human-in-the-loop into the drug-design workflow , moving from long-document ingestion through domain-specific question-answering and comparative historical analysis to actionable design insights and reverse translation; and (iii) expert evaluation on real-world pharmaceutical data : unlike prior work that relies

Read the complete text